The team at GABA Therapeutics is developing GRX-917, a new drug candidate expected to have a broad range of safe and effective therapeutic indications. The drug activates the production of brain neurosteroids which could benefit the lives of patients with life-altering neuropsychiatric, neurologic and pain disorders.
Many of these conditions represent some of the largest unmet medical needs in the United States and worldwide, including generalized anxiety disorder, anxious depression, postpartum depression, social anxiety disorder and panic disorder. The company will soon be initiating Phase 2/3 studies in anxiety and potentially various depression indications.
